Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.
Beats and misses reported Nov 18, 2025 – Nov 18, 2026
Ranked by EPS surprise % (highest first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | iRhythm Technologies, Inc. | Healthcare | Nov 5, 2026 | $0.82↑ Raised | $0.02 | +5190% | -32.7% | |
Quentin Blackford, President and Chief Executive Officer Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. | ||||||||
| 2 | BillionToOne, Inc. | Healthcare | May 6, 2026 | $0.34 | $0.01 | +3300% | +16.3% | |
| 3 | Caris Life Sciences, Inc. | Healthcare | Feb 26, 2026 | $0.28 | $0.01 | +2700% | +10.0% | |
| 4 | Lakefront Biotherapeutics N.V. | Healthcare | Feb 23, 2026 | $16.38 | $1.00 | +1538% | +1.8% | |
| 5 | BioCryst Pharmaceuticals, Inc. | Healthcare | Feb 26, 2026 | $1.12 | $0.07 | +1500% | +15.9% | |
| 6 | Corcept Therapeutics Incorporated | Healthcare | Jul 29, 2026 | $0.36 | $0.02 | +1381% | +25.6% | |
| 7 | Legend Biotech Corporation | Healthcare | Nov 10, 2026 | $0.14 | $0.01 | +1300% | -16.0% | |
| 8 | Hinge Health, Inc. | Healthcare | Feb 10, 2026 | $0.49 | $0.04 | +1125% | +20.5% | |
| 9 | ACADIA Pharmaceuticals Inc. | Healthcare | Feb 25, 2026 | $1.60 | $0.14 | +1068% | +0.2% | |
| 10 | Alnylam Pharmaceuticals, Inc. | Healthcare | Oct 29, 2026 | $16.26 | $1.66 | +880% | -25.1% | |
| 11 | Cronos Group Inc. | Healthcare | Aug 6, 2026 | $0.09 | $0.01 | +800% | +14.0% | |
Mike Gorenstein, Chairman, President and CEO Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign | ||||||||
| 12 | iRhythm Technologies, Inc. | Healthcare | Feb 19, 2026 | $0.17 | $0.02 | +750% | -1.9% | |
| 13 | Cronos Group Inc. | Healthcare | May 11, 2026 | $0.04 | $0.01 | +700% | +9.1% | |
Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy and as additional supply from the expansion at Cronos GrowCo fuels our next phase of growth. | ||||||||
| 14 | Agilon Health, Inc. | Healthcare | Aug 5, 2026 | $1.04↑ Raised | $0.14 | +622% | -8.4% | |
Tim O’Rourke, Chief Executive Officer Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model. | ||||||||
| 15 | STAAR Surgical Company | Healthcare | May 13, 2026 | $0.38 | $0.05 | +601% | +13.6% | |
STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion. | ||||||||
| 16 | Centene Corp. | Healthcare | Oct 27, 2026 | $0.58↑ Raised | $0.10 | +506% | +1.0% | |
Sarah M. London, Chief Executive Officer Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated, | ||||||||
| 17 | CareDx, Inc | Healthcare | Feb 24, 2026 | $0.12 | $0.02 | +503% | -1.8% | |
| 18 | Innoviva, Inc. | Healthcare | Feb 25, 2026 | $1.94 | $0.34 | +471% | +0.5% | |
| 19 | Fortrea Holdings Inc. | Healthcare | May 5, 2026 | $0.16— Maintained | $0.03 | +433% | +27.7% | |
We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion. | ||||||||
| 20 | AMN Healthcare Services, Inc. | Healthcare | Nov 5, 2026 | $1.16↓ Lowered | $0.23 | +406% | -24.2% | |
Cary Grace, President and Chief Executive Officer We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation, | ||||||||
| 21 | Alignment Healthcare, Inc. | Healthcare | Apr 30, 2026 | $0.05↑ Raised | $0.01 | +400% | -6.7% | |
John Kao, founder and CEO Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change. | ||||||||
| 22 | Vericel Corporation | Healthcare | Nov 5, 2026 | $0.27↑ Raised | $0.06 | +371% | +20.1% | |
Nick Colangelo, President and CEO The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders. | ||||||||
| 23 | Arcutis Biotherapeutics, Inc. | Healthcare | Feb 25, 2026 | $0.13 | $0.03 | +333% | +5.9% | |
| 24 | Nutex Health, Inc. | Healthcare | Nov 19, 2025 | $7.76 | $1.81 | +329% | +43.5% | |
| 25 | AMN Healthcare Services, Inc. | Healthcare | Aug 6, 2026 | $0.77— Maintained | $0.19 | +308% | +9.8% | |
Cary Grace, President and Chief Executive Officer We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions. | ||||||||
Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels.
Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign
Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy and as additional supply from the expansion at Cronos GrowCo fuels our next phase of growth.
Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.
STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion.
Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,
We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion.
We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation,
Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.
The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.
We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.
Ranked by EPS miss % (worst first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascentage Pharma Group International | Healthcare | Aug 20, 2026 | -$1.28 | $0.02 | -7850% | -5.7% | |
| 2 | Madrigal Pharmaceuticals, Inc. | Healthcare | Feb 19, 2026 | -$2.57 | $0.04 | -6525% | -11.5% | |
| 3 | BioCryst Pharmaceuticals, Inc. | Healthcare | May 6, 2026 | -$2.98 | $0.06 | -5067% | -1.4% | |
| 4 | Hims & Hers Health, Inc. | Healthcare | May 11, 2026 | -$0.40↑ Raised | $0.03 | -1675% | -11.5% | |
2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform. | ||||||||
| 5 | Xeris Biopharma Holdings, Inc. | Healthcare | Aug 6, 2026 | -$0.18 | $0.01 | -1588% | -2.2% | |
| 6 | Molina Healthcare, Inc. | Healthcare | Feb 5, 2026 | -$2.75 | $0.43 | -740% | -26.0% | |
| 7 | Mirum Pharmaceuticals, Inc. | Healthcare | Feb 25, 2026 | -$0.11 | $0.02 | -650% | -14.2% | |
| 8 | AdaptHealth Corp. | Healthcare | May 5, 2026 | -$0.06↑ Raised | $0.01 | -580% | -12.4% | |
The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance. | ||||||||
| 9 | PTC Therapeutics, Inc. | Healthcare | Oct 29, 2026 | -$0.62↑ Raised | $0.14 | -532% | -7.0% | |
Matthew B. Klein, M.D., Chief Executive Officer We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. | ||||||||
| 10 | InnovAge Holding Corp. | Healthcare | May 5, 2026 | -$0.22↑ Raised | $0.06 | -467% | -0.6% | |
We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance. | ||||||||
| 11 | Liquidia Corporation | Healthcare | Nov 10, 2026 | -$2.64 | $0.96 | -375% | +7.4% | |
Dr. Roger Jeffs, Chief Executive Officer Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy. | ||||||||
| 12 | Hims & Hers Health, Inc. | Healthcare | Nov 9, 2026 | -$0.14~ Mixed | $0.06 | -349% | -16.6% | |
Andrew Dudum, co-founder and CEO In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them. | ||||||||
| 13 | Innoviva, Inc. | Healthcare | Nov 4, 2026 | -$1.03— Maintained | $0.52 | -300% | -8.1% | |
Pavel Raifeld, Chief Executive Officer IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales. | ||||||||
| 14 | Nanobiotix S.A. | Healthcare | Mar 31, 2026 | -$0.46 | $0.30 | -251% | +11.4% | |
| 15 | BioMarin Pharmaceutical Inc. | Healthcare | Feb 23, 2026 | -$0.24 | $0.17 | -242% | -2.3% | |
| 16 | STAAR Surgical Company | Healthcare | Mar 3, 2026 | -$0.20 | $0.18 | -211% | +0.9% | |
| 17 | Brookdale Senior Living Inc. | Healthcare | May 6, 2026 | -$0.03 | $0.03 | -200% | -3.4% | |
| 18 | Cronos Group Inc. | Healthcare | Feb 26, 2026 | -$0.00 | $0.01 | -147% | -3.6% | |
| 19 | Azenta, Inc. | Healthcare | May 6, 2026 | -$0.04↓ Lowered | $0.10 | -140% | -24.5% | |
Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America. | ||||||||
| 20 | Caris Life Sciences, Inc. | Healthcare | Aug 5, 2026 | -$0.00↑ Raised | $0.01 | -139% | +24.2% | |
David Dean Halbert, Founder, Chairman and CEO This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine. | ||||||||
| 21 | Telix Pharmaceuticals Limited | Healthcare | Feb 19, 2026 | -$0.01 | $0.03 | -135% | +20.0% | |
| 22 | UroGen Pharma Ltd. | Healthcare | Nov 4, 2026 | -$0.03↓ Lowered | $0.11 | -128% | -25.2% | |
Liz Barrett, President and Chief Executive Officer We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity. | ||||||||
| 23 | Takeda Pharmaceutical Company Limited | Healthcare | May 13, 2026 | -$0.05 | $0.21 | -123% | +1.3% | |
| 24 | Sarepta Therapeutics, Inc. | Healthcare | Aug 5, 2026 | -$0.05 | $0.22 | -123% | +2.4% | |
| 25 | Halozyme Therapeutics, Inc. | Healthcare | Feb 17, 2026 | -$0.24 | $2.15 | -111% | -7.8% | |
2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform.
The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance.
We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.
We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance.
Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy.
In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.
IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.
Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America.
This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.
We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.